Geographic Atrophy

Pegcetacoplan injection showed increased benefit for subfoveal GA, with as few as 6 injections, over 3 years in the GALE extension trial.

In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.

Gildeuretinol showed a clinically meaningful reduction in geographic atrophy lesion growth and a favorable safety profile at 24 months in the Phase 3 SAGA trial.

This August 2024 month in review highlights updates to the ophthalmic pipeline, metformin for geographic atrophy, and decreasing rates of postoperative endophthalmitis in the US.

A new treatment era was born with first-time geographic atrophy approvals in 2023, but many are still searching for the next addition to the treatment landscape.

Our July 2024 month in review in ophthalmology includes the latest updates to the ophthalmological pipeline and a trio of studies on the treatment landscape for retinal diseases.

Geographic atrophy in eyes with dry AMD and macular atrophy in fellow eyes with neovascular AMD demonstrate similar growth rates.

Phase 2 data from the ARCHER study shows a protective effect of ANX007 on visual acuity and anatomical measures in the central macula in patients with GA.

We break down 5 top trials to keep an eye on at ASRS 2024, taking place in Stockholm, Sweden from July 17 to 20, 2024.

Our June 2024 month-in-review includes the latest pipeline news, the impact of vision issues on public health, and expert-led insight on the latest in ophthalmology.

Across the Phase 2 ReCLAIM-2 trial, elamipretide demonstrated photoreceptor protection and the potential for visual function improvement in eyes with dry AMD.

Arshad Khanani, MD breaks down the current treatment options for geographic atrophy and provides insight into the therapeutic pipeline.

These data pointed to a low risk of persistent IOP increases of intravitreous 0.1-mL injection volumes administered for 1 year in eyes with GA.

This month-in-review features an exclusive interview with Srinivas R. Sadda, MD, and promising data from studies on geographic atrophy, diabetic macular ischemia, diabetic retinopathy, and AMD.

At ARVO 2024, Dimitra Skondra, MD, describes the association between metformin use and decreased new-onset ICD coding of GA.

At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.

A higher dietary intake of several nutrients was strongly associated with slower progression toward the central macula in eyes with non-central GA.

At ARVO 2024, Ashkan Abbey, MD describes key data from the pivotal OAKS and DERBY, and the GALE extension trial over 3 years of pegcetacoplan treatment.

Metformin demonstrated a protective effect against new-onset geographic atrophy, which persisted and was more pronounced in individuals without diabetes.

Oral minocycline was not associated with a decrease in GA enlargement over 24 months, compared with the run-in phase, in a recent phase 2 nonrandomized trial.

Data from the phase 2 METforMIN trial do not support the use of oral metformin for reducing the progression of geographic atrophy.

Chief among a flurry of clinical advances in retina disease this year were the FDA approvals of complement inhibitors for GA and a higher-dose aflibercept for diabetic retinopathy. What comes next?

At AAO 2023, David Lally, MD describes results from the phase 2 ARCHER study and the potential benefit of intravitreal ANX007 for patients with GA.

Veeral Sheth, MD, MBA discusses the 3 improvements needed for the future of treating patients with geographic atrophy.

David Lally, MD highlights safety signals observed with GA therapies in clinical trials and the future of the treatment landscape.

Veeral Sheth, MD, MBA discusses safety signals reported with the use of approved therapies for geographic atrophy and the importance of real-world datasets.

David Lally, MD describes individual phenotypic features in geographic atrophy and determining patient response to treatment.

Veeral Sheth, MD, MBA, discusses how clinicians are beginning to use these therapies and the patient reaction to the availability of treatments for GA.

Veeral Sheth, MD, MBA, discusses the clinical trial data that led to FDA approval of SYFOVRE and IZERVAY for geographic atrophy.

David Lally, MD describes the association of the complement system with geographic atrophy and how the 2 FDA-approved therapies for GA work to block the complement system.